Q4 2025 Arcutis Biotherapeutics Inc Earnings Call Transcript

Feb 25, 2026 / 09:30 PM GMT

Release Date Price: $27.01 (+0.11%)

Transcript 10-K8-K

Key Points

Positve

Arcutis Biotherapeutics Inc (ARQT) reported a 123% year-on-year increase in net product revenues, reaching $372 million in 2025.
The company achieved positive cash flow in Q4 2025 and expects to maintain positive cash flow throughout 2026.
Zarif, the company's flagship product, has become the number one branded non-steroidal topical treatment across all approved indications.
FDA approvals for Zarif foam and cream have expanded treatment options for patients with psoriasis and atopic dermatitis, including young children.
Arcutis Biotherapeutics Inc (ARQT) has expanded its dermatology sales force and is taking over promotion to primary care physicians and pediatricians, indicating a strategic push for further growth.

Negative

The company anticipates a typical reduction in net product revenues in Q1 2026 due to seasonality and patient deductible resets.
Zarif's non-preferred drug tier status in Medicare Part D could temper demand despite expanded access.
There is a potential for fluctuations between operating income and loss due to non-cash expenses such as stock compensation and milestone payments.
The company faces challenges in gaining full Medicare Part D coverage, with only one-third of recipients currently having access.
Arcutis Biotherapeutics Inc (ARQT) continues to face competition in the branded non-steroidal topical space, which could impact market share and pricing strategies.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ARQT.OQ - Arcutis Biotherapeutics Inc
Q4 2025 Arcutis Biotherapeutics Inc Earnings Call
Feb 25, 2026 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, thank you for standing by. Welcome to the Arcuus Biotherapeutic Incs 4th quarter fiscal year 2025 earnings conference call.

At this time, all participants are in a listen-only mode.

After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you would need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press 11 again. Please be advised that today's conference is being recorded. I would like now to turn the conference over to Brian Shulkoff, head of investor relations. Please go ahead.

---------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.